By joining the ranks of Y Combinator's Winter 22 batch, Actipulse Neuroscience is ready to accelerate the development of its clinical pipeline, most notably the start of their FDA pivotal trial to bring their proprietary non-invasive brain neuromodulation technology to the home of patients diagnosed with Major Depressive Disorder.
Read MoreSan Francisco, CA September 2, 2015: Green Visor Capital ("Green Visor") announces that it led Kash Corp.'s ("Kash") Series Seed round of financing. As part of Green Visor's investment, Joe Saunders will join Kash's board of directors and Sam Wen will serve as technical adviser. Joe and Sam serve as Chairman / General Partner and Venture Partner, respectively, at Green Visor.
Read More